FIELD: medicine; oncology.
SUBSTANCE: present group of inventions refers to treatment of triple negative breast cancer. That is ensured by administering PD-1 antagonist pembrolizumab in combination with eribulin in effective doses.
EFFECT: such combined therapy provides effective treatment of this type of breast cancer by synergetic action of the components of the combination.
18 cl, 8 dwg, 7 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF PD-1 ANTAGONIST, VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR AND CBP/BETA-CATENIN INHIBITOR FOR TREATING CANCER | 2020 |
|
RU2838452C1 |
| TIGIT ANTIBODY ADMINISTRATION REGIMEN FOR TREATING CANCER | 2019 |
|
RU2833669C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| METHODS OF COMBINED TREATMENT OF MALIGNANT NEOPLASMS, INCLUDING AGENTS BLOCKING CTLA-4 AND PD-1 | 2020 |
|
RU2833523C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN TREATING CANCER | 2016 |
|
RU2834309C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
